General
Moderna to ask US and European regulators to allow emergency use of COVID-19 vaccine
Pharmaceutical company Moderna Inc. has said it will ask US and European regulators to allow emergency use of its COVID-19 vaccine, so that it can be widely distributed.
Key points:
- Results from a late-stage study show the vaccine was 94.1 per cent effective with no serious safety concerns
- Moderna said the shot was consistently effective across age, race, ethnicity and gender demographics
- US Food and Drug Administration advisers are scheduled to meet on December 17 to review the trial data
The company said full late-stage study results had confirmed the shots offered strong protection, and that its vaccine was 94.1 per cent effective, with no serious safety concerns.
It also reported a 100 per cent success rate in preventing severe cases.
Continue Reading
-
Business24 hours agoHow to turn spare change into serious wealth on the ASX
-
Business23 hours agoBuy these ASX 200 growth shares for 10% to 35% returns
-
Noosa News22 hours agoSteven Walker-Ely’s murder conviction over footballer’s stabbing death set aside
-
Business23 hours ago5 top ASX ETFs to buy in October 2025